Tideglusib

Tideglusib (NP-12, NP031112) is a potent and irreversible small molecule glycogen synthase kinase 3 (GSK-3) inhibitor.

Clinical trials

Tideglusib has been evaluated in clinical trials for:

• Alzheimer's disease and progressive supranuclear palsy. Both clinical trials were discontinued in 2011 (PSP) and 2012 (Alzheimer's disease) due to lack of efficacy
• Congenital/juvenile-onset myotonic muscular dystrophy type I.

Research

Tideglusib is or has been under investigation for multiple applications:

• Tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. In 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled.
• Preclinical in vitro studies were carried out for neuroblastoma and ovarian cancer with significant ROS-induced apoptosis.
• Arrhythmogenic right ventricular cardiomyopathy as of 2025.

References